For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus
itself, but by an overactive inflammatory state. In fact, in some people the immune system …

The global COVID-19 pandemic is currently underway. In December 2020, the European
Agency of Medicine (EMA) licensed the first Sars-CoV-2 vaccine. Therapeutic management …

DEAR EDITOR, Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2)
infection disease (COVID-19) is a novel disease identified in a cluster of pneumonia in the …

Objectives The outbreak of COVID-19 posed the issue of urgently identifying treatment
strategies. Colchicine was considered for this purpose based on well-recognised anti …

Introduction Neutrophilia and high levels of proinflammatory cytokines and other mediators
of inflammation are common finds in patients with severe acute respiratory syndrome due to …

Introduction: Corona virus is a group of viruses that cause diseases in mammals and birds.
In humans, these families of viruses can cause respiratory infections from a mild form to fatal …

Actuality The course of the novel coronavirus disease (COVID-19) is unpredictable. In some
cases, it manifests as increasing inflammation that leads to a cytokine storm and irreversible …

Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is a matter of concern worldwide and a huge …

To recognize the period of exaggerated cytokine response in patients with coronavirus
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …

Background Previous research done in Bulgaria demonstrated a fivefold reduction in
mortality from COVID‐19 with increased doses of colchicine from two hospitals in the …